-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca licenses Dizal’s lung cancer drug Zegfrovy in deal worth up to USD 1.5 billion

PUBT·07/14/2026 06:28:17
Listen to the news
AstraZeneca licenses Dizal’s lung cancer drug Zegfrovy in deal worth up to USD 1.5 billion
  • AstraZeneca entered an exclusive global license with Dizal for Zegfrovy, an oral EGFR inhibitor for lung cancer, gaining worldwide development and commercialization rights.
  • Financial terms include an upfront payment of USD 600 million, up to USD 900 million in milestones, and tiered royalties on global sales.
  • Deal closing is expected in H2 2026, subject to regulatory clearances.
  • Zegfrovy is cleared in the US, China for previously treated EGFR exon 20 insertion NSCLC; a first-line filing is under FDA, China review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.